- iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices.
- One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to monitor patients after discharge, the physicians reduced hospital stays and potentially improved identification of arrhythmia by extending monitoring beyond typical inpatient assessments.
- The other studies used Zio XT for low-risk patients to screen for atrial fibrillation in patients aged 70 years and older, and Zio AT for high-risk patients to monitor for arrhythmias in patients after transcatheter aortic valve replacement. J.P. Morgan analysts in a Monday note said that "a greater body of evidence supporting the technology will be key as the company pushes to better educate physicians on the value of AT," adding that "when this is coupled with a smaller body of clinical data and a sales rep focus on XT over AT, we believe there is a meaningful opportunity in 2022 and beyond for iRhythm to improve the marketability" of the mobile cardiac telemetry device in a "significantly underpenetrated" market.
Read the rest of the article on MedTech Dive here.